Insider Transactions in Q4 2022 at Crinetics Pharmaceuticals, Inc. (CRNX)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.65%
|
$50,016
$16.0 P/Share
|
|
Dec 01
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.55%
|
$53,142
$17.84 P/Share
|
|
Nov 15
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.43%
|
$56,268
$18.72 P/Share
|
|
Nov 01
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.31%
|
$56,268
$18.52 P/Share
|
|
Oct 17
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.21%
|
$53,142
$17.73 P/Share
|
|
Oct 12
2022
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,100
+13.94%
|
$11,100
$1.91 P/Share
|
|
Oct 10
2022
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+50.0%
|
-
|
|
Oct 03
2022
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,126
-3.11%
|
$59,394
$19.64 P/Share
|